Who are Degarelix & Relugolix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lupron, Micronor, Relugolix + Estradiol + Norethindrone Acetate, Eligard (TM), GnRH agonist/antagonist, Gonadotropin-releasing Hormone Analog.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/degarelix-relugolix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Degarelix & Relugolix — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Degarelix & Relugolix (Degarelix & Relugolix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GnRH receptor antagonist. Area: Oncology.

phase 2 GnRH receptor antagonist GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Degarelix & Relugolix (Degarelix & Relugolix) — VA Office of Research and Development. Degarelix and Relugolix are GnRH receptor antagonists that inhibit the production of gonadotropin-releasing hormone, leading to a decrease in testosterone levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Degarelix & Relugolix TARGET	Degarelix & Relugolix	VA Office of Research and Development	phase 2	GnRH receptor antagonist	GnRH receptor
Lupron	leuprorelin	Accord Healthcare S.L.U.	marketed	Gonadotropin Releasing Hormone Receptor Agonist	GnRH receptors	1985-01-01
Micronor	norethisterone	Johnson & Johnson	marketed	Progestin	GnRH receptors	1962-01-01
Relugolix + Estradiol + Norethindrone Acetate	Relugolix + Estradiol + Norethindrone Acetate	Sumitomo Pharma Switzerland GmbH	marketed	GnRH antagonist combination with hormone replacement therapy	GnRH receptor (relugolix component)
Eligard (TM)	Eligard (TM)	Chesapeake Urology Research Associates	marketed	GnRH agonist	GnRH receptor
GnRH agonist/antagonist	GnRH agonist/antagonist	Memorial Sloan Kettering Cancer Center	marketed	GnRH agonist/antagonist	GnRH receptor
Gonadotropin-releasing Hormone Analog	Gonadotropin-releasing Hormone Analog	Rutgers, The State University of New Jersey	marketed	GnRH agonist	GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-22 — Lupron · 9617303 · US
2031-02-05 — Lupron · 8921326 · US

Sponsor landscape (GnRH receptor antagonist class)

Sumitomo Pharma Switzerland GmbH · 1 drug in this class
University of Michigan · 1 drug in this class
VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Degarelix & Relugolix — Competitive Intelligence Brief. https://druglandscape.com/ci/degarelix-relugolix. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing